Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel Dignass

Showing results (61-70 of 177) with videos related to

Pageof 18
Sort By:
Journal of Medical Economics|January 27, 2021
Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in GermanyAditya Sardesai, Axel Dignass, Peter Quon, et al.
BMC Gastroenterology|January 19, 2023
Characteristics, clinical outcomes and patient-reported outcomes of patients with ulcerative colitis receiving tofacitinib: a real-world survey in the United States and five European countriesAlessandro Armuzzi, Ailsa Hart, Joseph C Cappelleri, et al.
World Journal of Gastroenterology|July 2, 2010
Impact of pain on health-related quality of life in patients with inflammatory bowel diseaseAnja Schirbel, Anne Reichert, Stephanie Roll, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 19, 2006
Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitisChristian A Hudert, Karsten H Weylandt, Yan Lu, et al.
United European Gastroenterology Journal|February 14, 2018
Efficacy and safety of a novel high-dose mesalazine tablet in mild to moderate active ulcerative colitis: a double-blind, multicentre, randomised trialAxel Dignass, Robert Schnabel, Jacek Romatowski, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|July 16, 2003
Late graft loss after intestinal transplantation in an adult patient as a result of necrotizing enterocolitisAndreas Pascher, Cornelia Radke, Axel Dignass, et al.
Journal of Clinical Medicine|December 11, 2019
Short and Long-Term Effectiveness of Ustekinumab in Patients with Crohn's Disease: Real-World Data from a German IBD CohortAlica Kubesch, Laurenz Rueter, Karima Farrag, et al.
Pancreas|May 13, 2011
Effects of systemic administration of a local anesthetic on pain in acute pancreatitis: a randomized clinical trialPeter Layer, Hans-Joachim Bronisch, Utah Maria Henniges, et al.
United European Gastroenterology Journal|April 21, 2020
How to start a Young GI Section in your country: A cookbookVita Skuja, Radislav Nakov, Yasmijn van Herwaarden, et al.
Advances in Therapy|October 15, 2024
Efficacy and Safety of Advanced Therapies in Moderately-to-Severely Active Ulcerative Colitis: a Systematic Review and Network Meta-analysisAxel Dignass, Claire Ainsworth, Susanne Hartz, et al.
Pageof 18

Showing results (61-70 of 177) with videos related to

Sort By:
Pageof 18
Journal of Medical Economics|January 27, 2021
Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in GermanyAditya Sardesai, Axel Dignass, Peter Quon, et al.
BMC Gastroenterology|January 19, 2023
Characteristics, clinical outcomes and patient-reported outcomes of patients with ulcerative colitis receiving tofacitinib: a real-world survey in the United States and five European countriesAlessandro Armuzzi, Ailsa Hart, Joseph C Cappelleri, et al.
World Journal of Gastroenterology|July 2, 2010
Impact of pain on health-related quality of life in patients with inflammatory bowel diseaseAnja Schirbel, Anne Reichert, Stephanie Roll, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 19, 2006
Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitisChristian A Hudert, Karsten H Weylandt, Yan Lu, et al.
United European Gastroenterology Journal|February 14, 2018
Efficacy and safety of a novel high-dose mesalazine tablet in mild to moderate active ulcerative colitis: a double-blind, multicentre, randomised trialAxel Dignass, Robert Schnabel, Jacek Romatowski, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|July 16, 2003
Late graft loss after intestinal transplantation in an adult patient as a result of necrotizing enterocolitisAndreas Pascher, Cornelia Radke, Axel Dignass, et al.
Journal of Clinical Medicine|December 11, 2019
Short and Long-Term Effectiveness of Ustekinumab in Patients with Crohn's Disease: Real-World Data from a German IBD CohortAlica Kubesch, Laurenz Rueter, Karima Farrag, et al.
Pancreas|May 13, 2011
Effects of systemic administration of a local anesthetic on pain in acute pancreatitis: a randomized clinical trialPeter Layer, Hans-Joachim Bronisch, Utah Maria Henniges, et al.
United European Gastroenterology Journal|April 21, 2020
How to start a Young GI Section in your country: A cookbookVita Skuja, Radislav Nakov, Yasmijn van Herwaarden, et al.
Advances in Therapy|October 15, 2024
Efficacy and Safety of Advanced Therapies in Moderately-to-Severely Active Ulcerative Colitis: a Systematic Review and Network Meta-analysisAxel Dignass, Claire Ainsworth, Susanne Hartz, et al.
Pageof 18